SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020

Sheila F Lumley, David W Eyre, Anna L McNaughton, Alison Howarth, Sarah Hoosdally, Stephanie B Hatch, James Kavanagh, Kevin K Chau, Louise O Downs, Stuart Cox, Laura Dunn, Anita Justice, Susan Wareing, Kate Dingle, Justine Rudkin, Kathryn Auckland, Alexander Fyfe, Jai Bolton, Robert Paton, Alexander J MentzerKatie Jeffery, Monique I Andersson, Tim James, Tim E A Peto, Brian D Marsden, Gavin Screaton, Richard J Cornall, Paul Klenerman, Daniel Ebner, David I Stuart, Derrick W Crook, Nicole Stoesser, Stephen H Kennedy, Craig Thompson, Sunetra Gupta, Philippa C Matthews

Research output: Contribution to journalArticle (Academic Journal)peer-review

Abstract

SARS-CoV-2 IgG screening of 1,000 antenatal serum samples in the Oxford area, United Kingdom, between 14 April and 15 June 2020, yielded a 5.3% seroprevalence, mirroring contemporaneous regional data. Among the 53 positive samples, 39 showed in vitro neutralisation activity, correlating with IgG titre (Pearson's correlation p<0.0001). While SARS-CoV-2 seroprevalence in pregnancy cohorts could potentially inform population surveillance, clinical correlates of infection and immunity in pregnancy, and antenatal epidemiology evolution over time need further study.

Structured keywords

  • Covid19

Keywords

  • Adolescent
  • Adult
  • Antibodies, Neutralizing/blood
  • Antibodies, Viral/blood
  • Betacoronavirus/immunology
  • COVID-19
  • Cohort Studies
  • Coronavirus Infections/blood
  • England/epidemiology
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Immunoglobulin G/blood
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral/blood
  • Population Surveillance
  • Pregnancy
  • Pregnancy Complications, Infectious/blood
  • Pregnancy Trimester, First/blood
  • Prenatal Diagnosis
  • Prevalence
  • SARS-CoV-2
  • Seroepidemiologic Studies
  • Single-Blind Method
  • Young Adult

Fingerprint Dive into the research topics of 'SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020'. Together they form a unique fingerprint.

Cite this